Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management

Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management is organized by PVI, PeerView Institute for Medical Education.

Release Date: February 14, 2024
Expiration Date: February 13, 2025

Activity Description and Educational Objectives:
It’s well known that increased low-density lipoprotein cholesterol (LDL-C) levels are linked to a higher risk of atherosclerotic cardiovascular disease (ASCVD). Another potent contributor to ASCVD that has recently emerged as a compelling treatment target is lipoprotein(a) (Lp[a]), a genetically influenced blood lipoprotein that resembles LDL cholesterol and exerts an independent impact on ASCVD risk. Assessing elevated LDL-C and Lp(a) can aid in more accurate risk assessment and guide personalized treatment strategies to reduce the risk of ASCVD. How should this new knowledge change patient evaluation and treatment approaches in cardiology practices?

Watch and listen as the esteemed Dr. Wright shares the latest data and treatment strategies for hyperlipidemia. Learners will come away from this activity with updated knowledge about the long-term consequences of elevated LDL-C, the role of Lp(a), and how to accurately assess ASCVD risk by screening Lp(a). Once an appropriate patient is identified, learn the pros and cons of current and emerging therapies—including PCSK9-targeting agents, novel small interfering RNAs, and ligand-conjugated antisense oligonucleotides—and how to choose the best option for individual patients to mitigate their ASCVD risk. PLUS, getting your CME credit is fast and easy with this Q&A-as-you-go format!

Upon completion of this activity, participants should be better able to:

• Describe the long-term consequences of elevated LDL-C levels and the role of lipoprotein(a) (Lp[a]) as an independent, causal risk factor in the pathophysiology of ASCVD
• Implement Lp(a) screening as a vital component of comprehensive ASCVD risk assessment and management
• Evaluate the safety and efficacy of current and emerging targeted therapies for cardiovascular event reduction and hyperlipidemia management in patients at risk of ASCVD, particularly those with statin intolerance or for whom maximally dosed statin is insufficient
• Design individualized hyperlipidemia treatment regimens for patients with elevated risk of ASCVD in consideration of current guidelines, patient needs, and the latest clinical evidence